Lochmüller Lab

We are pleased to announce that Dr. Hanns Lochmüller’s Tier 1 Canada Research Chair (CRC) in Neuromuscular Genomics and Health has been renewed through the Tri-agency Institutional Programs Secretariat. The renewed Chair will continue through 2032, supporting Hanns’ world-class research program in Canada.

The Canada Research Chairs Program invests up to $311 million annually to attract and retain some of the world’s most promising and accomplished researchers. Chairholders contribute to scientific discovery, strengthen Canada’s global research competitiveness, and help train the next generation of scientists and clinicians through mentorship, teaching, and collaborative research leadership.

Dr. Hanns Lochmüller

The Canada Research Chairs Program invests up to $311 million annually to attract and retain some of the world’s most promising and accomplished researchers. Chairholders contribute to scientific discovery, strengthen Canada’s global research competitiveness, and help train the next generation of scientists and clinicians through mentorship, teaching, and collaborative research leadership.

Hanns was originally recruited to The University of Ottawa from Europe through the CRC program and has since built an internationally recognized research program focused on rare neuromuscular diseases. With this renewed appointment, his team will continue advancing research in molecular therapies for neuromuscular disorders, genomic approaches to diagnostics and gene discovery, and clinical research and care for patients living with rare neuromuscular disorders.

“I am very grateful for the continued trust and support of the Canadian government and the scientific community. This renewed award enables us to advance our research program in partnership with our hospitals in Ottawa, as well as nationally through NMD4C and MDC.”
-Hanns Lochmüller